Optimizing the Anticoagulation Regimen of Enoxaparin During Percutaneous Coronary Intervention (OPTIENOX-PCI)

NCT03145675 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

378

Enrollment

OTHER

Sponsor class

Conditions

Coronary Artery Disease
Percutaneous Coronary Intervention

Interventions

DRUG: Enoxaparin (Staged-dose PCI Group)
DRUG: Enoxaparin (Single-dose PCI Group)
DRUG: Enoxaparin (High-dose Group)
DRUG: Enoxaparin (Standard-dose Group)

Sponsor

Peking Union Medical College Hospital